Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giorgio Facheris
Observed name:
G. Facheris
Institutions:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
University of Brescia
Observed institutions:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
University of Brescia
ORCID:
0000-0002-4555-1725
Observed ORCID:
0000-0002-4555-1725
OpenAlex ID:
A5072320156
Home-based pulmonary rehabilitation in patients undergoing (chemo)radiation therapy for unresectable lung cancer: a prospective explorative study
2022
·
Paolo Borghetti
, Jacopo Branz
, et al.
·
La radiologia medica
·
24
PDF
Adoption of Hybrid MRI-Linac Systems for the Treatment of Brain Tumors: A Systematic Review of the Current Literature Regarding Clinical and Technical Features
2023
·
Andrea Emanuele Guerini
, Stefania Nici
, et al.
·
Technology in Cancer Research & Treatment
·
16
Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice
2020
·
Michela Buglione
, Luigi Spiazzi
, et al.
·
Radiation Oncology
·
15
PDF
Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis
2026
·
Pietro Bertoglio
, Filippo Tommaso Gallina
, et al.
·
European Journal of Surgical Oncology
·
12
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment
2022
·
Andrea Emanuele Guerini
, Alessandra Tucci
, et al.
·
Cancers
·
12
PDF
Adaptive radiotherapy for oropharyngeal cancer with daily adapt-to-shape workflow on 1.5 T MRI-linac: Preliminary outcomes and comparison with helical tomotherapy
2025
·
Andrea Emanuele Guerini
, Michela Buglione
, et al.
·
Clinical and Translational Radiation Oncology
·
11
PDF
Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience
2023
·
Paolo Borghetti
, Giulia Volpi
, et al.
·
Frontiers in Oncology
·
9
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials
2025
·
Francesco Guerrera
, Filippo Tommaso Gallina
, et al.
·
Lung Cancer
·
8
Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review
2025
·
Giorgio Facheris
, Gianluca Cossali
, et al.
·
Cancers
·
7
Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma
2024
·
Andrea Emanuele Guerini
, Eneida Mataj
, et al.
·
Advances in Radiation Oncology
·
3
PDF
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort
2023
·
Paolo Borghetti
, Giorgio Facheris
, et al.
·
Clinical Lung Cancer
·
3
PDF
Ambient air pollution and survival in SCLC/LCNEC: Analysis of a single centre retrospective cohort
2025
·
Luca Carlofrancesco Ammoni
, Valentina Cortesi
, et al.
·
European Journal of Cancer
·
2
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)
2025
·
Paolo Borghetti
, Rolando D’Angelillo
, et al.
·
Lung Cancer
·
2
A Brief Report on the Role of SPECT/TC in the Optimization of Radiotherapy Treatment with Radical Intent for Unresectable Stage III NSCLC
2022
·
Jessica Imbrescia
, Giulia Volpi
, et al.
·
Applied Sciences
·
2
PDF
Magnetic Resonance Guided Radical Radiation Therapy for Prostate Cancer in the Presence of Bilateral Hip Prostheses: First Experience With a 1.5 T Magnetic Resonance Linear Accelerator
2025
·
Andrea Emanuele Guerini
, Stefania Nici
, et al.
·
Advances in Radiation Oncology
·
1
PDF
Treatment of Non-Hodgkin Lymphoma Involving Head and Neck Sites with a 1.5 T MR-Linac: Preliminary Results from a Prospective Observational Study
2025
·
Andrea Emanuele Guerini
, Stefania Nici
, et al.
·
Hematology Reports
·
1
PD-0962 Second PFS after post-PACIFIC relapse in the Blue Sky observational study on stage 3 NSCLC.
2023
·
A.R. Filippi
, J. Saddi
, et al.
·
Radiotherapy and Oncology
·
1
Multidisciplinary Management of Stage III NSCLC in the Immunotherapy Era: An Italian Delphi Consensus from AIOM, SICT, SIAPEC, and AIRO
2026
·
Filippo T. Gallina
, Francesca Ambrosi
, et al.
·
JTO Clinical and Research Reports
CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression
2026
·
Andrea Emanuele Guerini
, Sara Pedretti
, et al.
·
Immuno
2241 Adaptive Accelerated Partial Breast Irradiation with a 1.5 T MR-linac using daily Adapt-to-shape workflow and Comprehensive Motion Management
2026
·
Andrea E Guerini
, Lanfranco Chirico
, et al.
·
Radiotherapy and Oncology
2904 Assessment of PET-CT based pre-treatment risk factors to predict the dose to OARs in patients with Hodgkin Lymphoma involving the mediastinum
2026
·
Andrea E Guerini
, Mariateresa Cefaratti
, et al.
·
Radiotherapy and Oncology
Role of Cytokines in Oligometastatic Non-Small-Cell Lung Cancer Treated with Stereotactic Radiation Therapy: An Observational Pilot Study
2026
·
Giorgio Facheris
, Alessio Bruni
, et al.
·
Biomolecules
PDF
EP.08.03 Surgical Outcomes in Induction and Perioperative Chemoimmunotherapy Trials: A Meta Analysis
2025
·
P. Bertoglio
, F. Gallina
, et al.
·
Journal of Thoracic Oncology
2022 Use of Unity MRI-linac for the treatment of non-Hodgkin lymphoma head and neck sites: preliminary experience from a prospective observational study.
2025
·
Andrea Emanuele Guerini
, Luigi Spiazzi
, et al.
·
Radiotherapy and Oncology
3985 Ultra-fast Adapt-To-Shape (ATS) optimization in online MRI-guided Adaptive Radiotherapy (MRgART) for H&N and brain cancers
2025
·
Lanfranco Chirico
, Stefania Nici
, et al.
·
Radiotherapy and Oncology
Show more works
View as search
Works count:
30
Citation count:
129
H-index:
8
I10-index:
6
Year
Topic
Type